Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This randomized trial studies transdermal or oral telapristone acetate in treating patients
undergoing surgery to remove the breast (mastectomy). Telapristone acetate may help prevent
breast cancer from forming in premenopausal women. Giving telapristone acetate transdermally
may be safer and have fewer side effects than oral administration.